New menopause drug to target hot flashes without hormones gets FDA approval

Bayer has secured FDA approval for elinzanetant, branded as Lynkuet, a new once-daily, non-hormonal oral treatment for moderate to severe menopausal hot flashes, with a U.S. launch anticipated in November. This approval addresses a significant market gap for women who cannot or choose not to use hormone replacement therapy, offering an alternative to existing treatments like Astellas' fezolinetant, which operates via a similar mechanism. Clinical trials demonstrated a greater than 73% reduction in hot flash frequency, positioning Lynkuet as a key entrant in the growing non-hormonal women's health segment.

Analysis

Bayer has received FDA approval for elinzanetant, branded Lynkuet, a once-daily, non-hormonal oral treatment for moderate to severe menopausal hot flashes, with a US launch expected in November. This approval represents a significant product launch, targeting a substantial market where over 80% of women experience hot flashes. Lynkuet operates by blocking specific neurokinins in the brain, offering a novel mechanism of action.

The drug addresses a critical unmet need for women who cannot or choose not to use hormone replacement therapy, including those with certain underlying health conditions. Phase 3 clinical trials demonstrated a greater than 73% reduction in vasomotor symptom frequency over 12 weeks, significantly outperforming placebo's 47% reduction, with effects sustained over a year. This efficacy positions Lynkuet as a compelling alternative.

Lynkuet enters a competitive landscape, joining Astellas' fezolinetant, which was approved in 2023 and utilizes a similar neurokinin-blocking pathway. Bayer's entry expands treatment options, intensifying competition within the non-hormonal VMS therapy segment. This approval strengthens Bayer's pharmaceutical portfolio, leveraging a newly understood physiological pathway for menopause symptom management.

Key Decisions for Investors

• Investors should assess Bayer's potential revenue growth and market share capture from Lynkuet, given its strong clinical efficacy and the large, underserved market for non-hormonal menopause treatments.
• Monitor the competitive dynamics between Lynkuet and Astellas' fezolinetant post-launch to gauge market adoption rates and pricing strategies in this emerging therapeutic class.
• Consider the long-term impact on Bayer's pharmaceutical segment, as Lynkuet's sustained efficacy and first-line treatment potential could provide a durable revenue stream.